Navigation Links
NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
Date:8/5/2009

href="http://www.neurogesx.com/" target="_new">http://www.neurogesx.com.

A replay of the conference call will be available beginning August 7, 2009 at 12:00 p.m. ET (9:00 a.m. PT) and ending on August 17, 2009 by dialing 1-877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 329620. A replay of the webcast will also be available on the corporate website for one month, through September 7, 2009.

About NeurogesX, Inc.

NeurogesX (NASDAQ: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate Qutenza(TM), a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Qutenza is currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Qutenza will be marketed in the European Union and certain countries in Eastern Europe, the Middle East and Africa, by Astellas Pharma Europe, Ltd. In the United States, NeurogesX submitted a new drug application (NDA) for PHN to the U.S. Food and Drug Administration (FDA) which was accepted for filing by the FDA in December 2008 and has been given an extended Prescription Drug User Fee Act (PDUFA) date of November 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat p
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
2. NeurogesX Added to Russell 3000 Index
3. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
4. NeurogesX to Present at Needham Life Sciences Conference
5. NeurogesX Receives European Commission Approval for Qutenza(TM)
6. NeurogesX Reports First Quarter 2009 Results
7. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
8. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
9. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
10. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
11. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
(Date:7/10/2014)... researchers have observed the fractional quantum Hall effect in ... matter can be tuned by an electric field. ... when electrons confined to thin sheets are exposed to ... behavior where thousands of individual electrons behave as a ... effect is well established, many details of this collective ...
Breaking Biology Technology:Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3
... North ... America, DEERFIELD, Ill., ... Cartago, Costa Rica has been,recognized with the 2008 Shingo Prize for Operational ... North America,-- is being honored for its achievements in driving higher quality ...
... announced today it,submitted to the U.S. Food & ... Application (BLA) for motavizumab, an investigational,monoclonal antibody (MAb) ... supported by clinical trial data from more than ... of serious disease,caused by respiratory syncytial virus (RSV) ...
... Unique and Innovative Formulation Available Without a ... Prescription ... today announced the,launch of PSORENT, a clinically proven, steroid-free, ... which has,proven efficacy against psoriasis symptoms, in a novel, ...
Cached Biology Technology:Baxter's Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing 2MedImmune Submits Biologics License Application to FDA for Motavizumab 2MedImmune Submits Biologics License Application to FDA for Motavizumab 3NeoStrata(R) Announces the Launch of PSORENT(TM) Psoriasis Topical Treatment 2
(Date:7/11/2014)... researchers from The Chinese University of Hong Kong, BGI ... soybean linked to salt tolerance, with implication for improving ... study published online in Nature Communications provides ... crop improvement. , Soybean is an important crop for ... soybeans have less genetic diversities than their wild counterparts. ...
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/11/2014)... cannabinoid receptor type 1 can inhibit voltage-gated ... reduce neurotransmitter release. However, some scholars demonstrated ... extracellular Ca2+ influx and increase neurotransmitter release. ... Hospital Affiliated to Tongji Medical College, Huazhong ... whole cell voltage-clamp and calcium imaging in ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... for benefiting degenerative diseases, and do so by invoking ... manner compatible with clinical use (i.e., without animal feeder ... were a few of a number of conclusions arrived ... Snyder, M.D., Ph.D., and spearheaded by a member of ...
... ability to discern one sex from another may depend ... nerve cells, and the number of receptors is controlled ... Illinois at Chicago researchers have found. , Everything from ... illnesses such as amyotrophic lateral sclerosis, muscular dystrophy, post-traumatic ...
... the first large-scale study to evaluate a candidate HIV ... study collaborators in the United States and South Africa. ... five sites throughout South Africa and is expected to ... of the HIV Vaccine Trials Network (HVTN), which is ...
Cached Biology News:Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 2Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 3Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 4Stem cells act through multiple mechanisms to benefit mice with neurodegenerative disease 5Bisexual fruit flies show new role for neurochemical 2Africa's first large-scale HIV vaccine study launches 2Africa's first large-scale HIV vaccine study launches 3Africa's first large-scale HIV vaccine study launches 4